ATE520703T1 - Einsatz von squalenhaltiger säure für die formulierung eines aktiven prinzips im nanoteilchenzustand - Google Patents
Einsatz von squalenhaltiger säure für die formulierung eines aktiven prinzips im nanoteilchenzustandInfo
- Publication number
- ATE520703T1 ATE520703T1 AT09152764T AT09152764T ATE520703T1 AT E520703 T1 ATE520703 T1 AT E520703T1 AT 09152764 T AT09152764 T AT 09152764T AT 09152764 T AT09152764 T AT 09152764T AT E520703 T1 ATE520703 T1 AT E520703T1
- Authority
- AT
- Austria
- Prior art keywords
- formulation
- active principle
- derivatives
- difluoro
- nanoparticles
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 5
- 239000002253 acid Substances 0.000 title abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 title 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 title 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940031439 squalene Drugs 0.000 title 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical class O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002798 polar solvent Substances 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 235000011178 triphosphate Nutrition 0.000 abstract 1
- 239000001226 triphosphate Substances 0.000 abstract 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1
- 239000012873 virucide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Composite Materials (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0451365A FR2874016B1 (fr) | 2004-06-30 | 2004-06-30 | Nanoparticules de derives de la gemcitabine |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE520703T1 true ATE520703T1 (de) | 2011-09-15 |
Family
ID=34945701
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05857322T ATE519773T1 (de) | 2004-06-30 | 2005-06-23 | Nanopartikel aus gemcitabinderivaten |
AT09152764T ATE520703T1 (de) | 2004-06-30 | 2005-06-23 | Einsatz von squalenhaltiger säure für die formulierung eines aktiven prinzips im nanoteilchenzustand |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05857322T ATE519773T1 (de) | 2004-06-30 | 2005-06-23 | Nanopartikel aus gemcitabinderivaten |
Country Status (11)
Country | Link |
---|---|
US (2) | US7704972B2 (de) |
EP (3) | EP1761551B1 (de) |
JP (2) | JP4927726B2 (de) |
CN (2) | CN101061131B (de) |
AT (2) | ATE519773T1 (de) |
CA (2) | CA2805761C (de) |
DK (2) | DK2055711T3 (de) |
ES (2) | ES2372141T3 (de) |
FR (1) | FR2874016B1 (de) |
PT (2) | PT1761551E (de) |
WO (1) | WO2006090029A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2648099C (en) * | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
FR2924024B1 (fr) * | 2007-11-27 | 2012-08-17 | Centre Nat Rech Scient | Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse |
FR2931152B1 (fr) * | 2008-05-16 | 2010-07-30 | Centre Nat Rech Scient | Nouveau systeme de transfert d'acide nucleique |
WO2010039039A1 (en) * | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
FR2937549B1 (fr) * | 2008-10-29 | 2011-04-01 | Centre Nat Rech Scient | Nanoparticules de derives beta-lactamine |
FR2937537A1 (fr) * | 2008-10-29 | 2010-04-30 | Centre Nat Rech Scient | Nanoparticules de statine |
EP2344277B1 (de) * | 2008-10-31 | 2018-06-27 | Hitachi Koki CO., LTD. | Zentrifuge |
WO2010063080A1 (en) | 2008-12-05 | 2010-06-10 | Commonwealth Scientific And Industrial Research Organisation | Amphiphile prodrugs |
FR2968662B1 (fr) | 2010-12-10 | 2013-11-22 | Roussy Inst Gustave | Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation |
JP6049712B2 (ja) | 2011-07-08 | 2016-12-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill | 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子 |
FR2988092B1 (fr) * | 2012-03-16 | 2014-04-25 | Centre Nat Rech Scient | Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique |
US8956613B2 (en) | 2012-11-13 | 2015-02-17 | BoYen Therapeutics, Inc. | Gemcitabine prodrugs and uses thereof |
EP2742955A1 (de) | 2012-12-12 | 2014-06-18 | Centre National De La Recherche Scientifique | Nanopartikel auf Grundlage eines Biokonjugats von GAG |
JP6083770B2 (ja) * | 2013-09-13 | 2017-02-22 | 板井 昭子 | 水溶液製剤及びその製造方法 |
CN105873569B (zh) | 2013-11-06 | 2020-07-28 | 芝加哥大学 | 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体 |
CN103599073A (zh) * | 2013-11-15 | 2014-02-26 | 无锡中科光远生物材料有限公司 | 一种负载有靶向抗癌药物的plga微米颗粒的制备方法 |
JP6212831B2 (ja) | 2013-12-04 | 2017-10-18 | 杭州源昶医薬科技有限公司 | ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途 |
WO2015116782A1 (en) | 2014-01-29 | 2015-08-06 | Board Of Regents, The University Of Texas System | Nucleobase analogue derivatives and their applications |
CN105030682B (zh) * | 2015-06-24 | 2018-02-09 | 广州复大医疗股份有限公司 | 一种纳米微粒胶体及其制备方法与用途 |
US11246877B2 (en) | 2016-05-20 | 2022-02-15 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
TWI719182B (zh) * | 2017-03-29 | 2021-02-21 | 國立交通大學 | 奈米組成物、其製造方法及其用途 |
CN111491634A (zh) | 2017-07-31 | 2020-08-04 | 詹纽瑞治疗公司 | 有机磷酸酯衍生物 |
JP7364552B2 (ja) | 2017-08-02 | 2023-10-18 | ザ ユニバーシティ オブ シカゴ | X線誘起光線力学療法、放射線療法、放射線力学療法、化学療法、免疫療法、及びそれらの任意の組み合わせのための、ナノスケール金属有機層及び金属有機ナノプレート |
EP3758495A4 (de) * | 2018-03-02 | 2021-12-01 | January Therapeutics, Inc. | Nanopartikelzusammensetzungen |
WO2019204869A1 (en) * | 2018-04-26 | 2019-10-31 | NanoMed Holdings Pty Ltd | Gemcitabine amphiphile prodrugs |
EP3628735A1 (de) | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense-rna-targeting pmp22 zur behandlung der charcot-marie-tooth-1a-erkrankung |
WO2020247912A1 (en) * | 2019-06-06 | 2020-12-10 | Board Of Regents, The University Of Texas System | Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof |
US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
FR3110427B1 (fr) | 2020-05-20 | 2023-07-14 | Laboratoires Eriger | Conjugué terpenique de couplage |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9307043D0 (en) * | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
CA2278056C (en) * | 1997-01-24 | 2006-12-12 | Norsk Hydro Asa | Gemcitabine derivatives |
FR2808691B1 (fr) * | 2000-05-12 | 2005-06-24 | Coletica | Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine |
-
2004
- 2004-06-30 FR FR0451365A patent/FR2874016B1/fr active Active
-
2005
- 2005-06-23 PT PT05857322T patent/PT1761551E/pt unknown
- 2005-06-23 CN CN2005800218778A patent/CN101061131B/zh active Active
- 2005-06-23 EP EP05857322A patent/EP1761551B1/de active Active
- 2005-06-23 DK DK09152764.8T patent/DK2055711T3/da active
- 2005-06-23 JP JP2007518660A patent/JP4927726B2/ja active Active
- 2005-06-23 CA CA2805761A patent/CA2805761C/fr active Active
- 2005-06-23 PT PT09152764T patent/PT2055711E/pt unknown
- 2005-06-23 DK DK05857322.1T patent/DK1761551T3/da active
- 2005-06-23 EP EP08100379A patent/EP1925624A1/de not_active Withdrawn
- 2005-06-23 AT AT05857322T patent/ATE519773T1/de active
- 2005-06-23 ES ES09152764T patent/ES2372141T3/es active Active
- 2005-06-23 AT AT09152764T patent/ATE520703T1/de active
- 2005-06-23 EP EP09152764A patent/EP2055711B1/de active Active
- 2005-06-23 US US11/631,075 patent/US7704972B2/en active Active
- 2005-06-23 CN CN201110251937.2A patent/CN102335436B/zh active Active
- 2005-06-23 CA CA2572380A patent/CA2572380C/fr active Active
- 2005-06-23 WO PCT/FR2005/050488 patent/WO2006090029A1/fr active Application Filing
- 2005-06-23 ES ES05857322T patent/ES2371411T3/es active Active
-
2010
- 2010-03-04 US US12/717,639 patent/US8044034B2/en active Active
-
2011
- 2011-12-07 JP JP2011267891A patent/JP5552473B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP1761551A1 (de) | 2007-03-14 |
CA2805761C (fr) | 2016-10-04 |
CN101061131B (zh) | 2011-10-05 |
DK2055711T3 (da) | 2011-12-12 |
US7704972B2 (en) | 2010-04-27 |
JP2012102107A (ja) | 2012-05-31 |
CN102335436A (zh) | 2012-02-01 |
FR2874016B1 (fr) | 2006-11-24 |
CA2572380C (fr) | 2013-11-19 |
ES2372141T3 (es) | 2012-01-16 |
CN102335436B (zh) | 2014-10-08 |
EP1925624A1 (de) | 2008-05-28 |
ES2371411T3 (es) | 2012-01-02 |
FR2874016A1 (fr) | 2006-02-10 |
EP2055711A1 (de) | 2009-05-06 |
DK1761551T3 (da) | 2011-11-28 |
PT2055711E (pt) | 2011-12-07 |
CN101061131A (zh) | 2007-10-24 |
ATE519773T1 (de) | 2011-08-15 |
CA2572380A1 (fr) | 2006-08-31 |
JP2008504353A (ja) | 2008-02-14 |
EP2055711B1 (de) | 2011-08-17 |
US20100160249A1 (en) | 2010-06-24 |
PT1761551E (pt) | 2011-11-24 |
EP1761551B1 (de) | 2011-08-10 |
WO2006090029A1 (fr) | 2006-08-31 |
JP5552473B2 (ja) | 2014-07-16 |
US8044034B2 (en) | 2011-10-25 |
CA2805761A1 (fr) | 2006-08-31 |
JP4927726B2 (ja) | 2012-05-09 |
US20090130214A1 (en) | 2009-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE520703T1 (de) | Einsatz von squalenhaltiger säure für die formulierung eines aktiven prinzips im nanoteilchenzustand | |
US9700536B2 (en) | Topical formulations of tellurium-containing compounds | |
CA2535364A1 (en) | Hyaluronic acid nanoparticles | |
US10376500B2 (en) | Gel containing pirfenidone | |
NO20071853L (no) | Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose. | |
JP2003503348A5 (de) | ||
CR7718A (es) | Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso | |
JP2007523138A5 (de) | ||
MX2010001857A (es) | Composicion pesticida potenciada en eficacia y metodo para potenciar la eficacia de ingredientes activos pesticidas. | |
PH12014500367A1 (en) | Alkyl lactyllactates and processes of making the same | |
AR059113A1 (es) | Composicion para administracion topica | |
RU2012127776A (ru) | Растворимые пленки, содержащие высокие концентрации неионных поверхностно-активных веществ, таких как полисорбаты, для увеличения высоких нагрузок твердых продуктов | |
CN104853753A (zh) | 包含艾地苯醌、n-乙酰基-s-法呢基-l-半胱氨酸和麦角硫因的制剂及其用途 | |
PL370779A1 (en) | Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments | |
CA2529305A1 (en) | Self-tanning compositions comprising a water-soluble vitamin b3 compound and an alpha-hydroxycarbonyl self-tanning agent | |
DK1716845T3 (da) | Formulering til dermal anvendelse | |
EP1224932A4 (de) | Wirkstoffe zur hemmung des zelltods | |
CN102293213A (zh) | 一种碱性化纤油剂杀菌防腐剂及其制备方法 | |
JP4875026B2 (ja) | 精子運動活性化剤及び精子活性化方法 | |
PE20010346A1 (es) | Un complejo de eletriptan y un derivado de ciclodextrina adecuados para administracion por via intranasal | |
BRPI0805356B1 (pt) | composto retinóides para tratamento de acne atrofia da pele, foto-envelhecimento, rugas, linhas finas, marcas de esticamento ou celulite, composições cosméticas ou farmacêuticas compreendendo o referido composto e processo para a preparação das composições | |
CN104041510B (zh) | 一种含有丁香菌酯和三唑类杀菌剂的杀菌组合物 | |
Vermeiren et al. | Intrarectal nitric oxide administration prevents cellular infiltration but not colonic injury during dextran sodium sulfate colitis | |
AR054221A1 (es) | Vehiculos de fase unica no acuosos y formulaciones que utilizan tales vehiculos | |
CN108102082A (zh) | 聚己内酯基二乙基磺丙基甜菜碱及制备方法以及其作为药物释放载体的构建方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 2055711 Country of ref document: EP |